MolPort-001-759-081

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

107 Suppliers, 41 USDMF, 42 CEP/COS, 25 JDMF, 27 EU WC, 78 KDMF, 25 NDC API, 49 Listed Suppliers

DEVELOPMENTS

3 Drug(s) in Development

3 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

11 Suppliers

11 Suppliers

DOSSIERs // Finished Dosage Forms

842 Dossiers, 420 FDA Orange Book, 111 Europe, 134 Canada, 13 Australia, 35 South Africa, 129 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 10MG BASE, TABLET;ORAL - EQ 2.5MG BASE, TABLET;ORAL - EQ 5MG BASE, CAPSULE;ORAL - EQ 10MG BASE;20MG, CAPSULE;ORAL - EQ 10MG BASE;40MG, CAPSULE;ORAL - EQ 2.5MG BASE;10MG, CAPSULE;ORAL - EQ 5MG BASE;10MG, CAPSULE;ORAL - EQ 5MG BASE;20MG, CAPSULE;ORAL - EQ 5MG BASE;40MG, TABLET;ORAL - EQ 10MG BASE;14MG, TABLET;ORAL - EQ 2.5MG BASE;3.5MG, TABLET;ORAL - EQ 5MG BASE;7MG, TABLET;ORAL - EQ 10MG BASE;200MG, TABLET;ORAL - EQ 2.5MG BASE;200MG, TABLET;ORAL - EQ 5MG BASE;200MG, TABLET;ORAL - EQ 10MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 80MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 80MG BASE, TABLET;ORAL - EQ 10MG BASE;160MG, TABLET;ORAL - EQ 10MG BASE;320MG, TABLET;ORAL - EQ 5MG BASE;160MG, TABLET;ORAL - EQ 5MG BASE;320MG, TABLET;ORAL - EQ 10MG BASE;20MG, TABLET;ORAL - EQ 10MG BASE;40MG, TABLET;ORAL - EQ 5MG BASE;20MG, TABLET;ORAL - EQ 5MG BASE;40MG, TABLET;ORAL - EQ 10MG BASE;12.5MG;160MG, TABLET;ORAL - EQ 10MG BASE;25MG;160MG, TABLET;ORAL - EQ 10MG BASE;25MG;320MG, TABLET;ORAL - EQ 5MG BASE;12.5MG;160MG, TABLET;ORAL - EQ 5MG BASE;25MG;160MG, TABLET;ORAL - EQ 10MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 10MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 5MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 5MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers, 39 Kerry, 35 BASF, 23 Roquette, 21 SPI Pharma, 20 Microlex e.U, 16 Seppic, 13 Gangwal Chemicals, 12 Sigachi Industries, 12 Gangwal Healthcare, 12 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 11 Corel Pharma Chem, 11 Nanjing Well Pharmaceutical, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 7 Boai NKY Pharmaceuticals Ltd, 7 DFE Pharma, 7 Ideal Cures Pvt Ltd, 6 Lonza Capsugel, 5 Actylis, 5 Prachin Chemical, 5 Pharmatrans-Sanaq, 5 Ingredion Pharma Solutions, 4 Kima Chemical, 4 Vasa Pharmachem, 4 ACG Worldwide, 4 DKSH, 3 Alcedo Pharmachem, 3 Ulanqab Kema New Material, 3 The Dow Chemical Company, 3 Jai Radhe Sales, 3 Clariant, 3 Rochem International Inc, 2 Pfanstiehl, 2 Nomisma Healthcare, 2 Seqens, 2 Finar, 2 Aeon Procare, 2 Qualicaps, 1 Nanjing Bold Chemical, 1 Minakem, 1 Vertellus, 1 Avesta Pharma, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Shanghai Welltone Material Technology Co., Ltd, 1 NEWEDGE Overseas, 1 Pharm-RX Chemical, 1 Chynops Pharma

EXCIPIENTS BY APPLICATIONS

96 Fillers, Diluents & Binders, 57 Coating Systems & Additives, 51 Direct Compression, 48 Disintegrants & Superdisintegrants, 35 Solubilizers, 35 Controlled & Modified Release, 33 Thickeners and Stabilizers, 32 Lubricants & Glidants, 31 Granulation, 25 Topical, 23 Film Formers & Plasticizers, 22 Parenteral, 21 Chewable & Orodispersible Aids, 19 Taste Masking, 17 Co-Processed Excipients, 10 API Stability Enhancers, 10 Emulsifying Agents, 9 Empty Capsules, 7 Rheology Modifiers, 6 Surfactant & Foaming Agents, 4 Vegetarian Capsules, 2 Coloring Agents

GLOBAL SALES INFORMATION

60 US Medicaid Prescriptions, 102 Finished Drug Prices

MARKET PLACE

35 APIs, 7 DOSSIERS // FDF

PATENTS

31 US Patents, 6 Health Canada Patents

ANALYTICAL SOLUTION(s)

5 EDQM Standards, 1 USP Standards, 7 JP Standards, 1 Other Ref. Standards

DIGITAL CONTENT

5 Data Compilation & Company Tracker #PharmaFlow, 39 News

Find Clinical Drug Pipeline Developments & Deals for MolPort-001-759-081